SCTX

SEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 3

Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks

Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks

Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,088,888

F2 · price: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

F3 · balance_after: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.

F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

SEC source: 0000947871-26-000733 · ownership.xml · derivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 348,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000733 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,348,825

F2 · shares: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000733 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 348,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001231919-26-000813 · form4-07292026_110744.xml · derivative · entry 5

AH Bio Fund II, L.P. · CIK 0001725721 · 10% owner

AH Equity Partners Bio II, L.L.C. · CIK 0001725722 · 10% owner

AH Bio Fund III, L.P. · CIK 0001799477 · 10% owner

AH Equity Partners Bio III, L.L.C. · CIK 0001799478 · 10% owner

Andreessen Marc L · CIK 0001160077 · 10% owner

HOROWITZ BENJAMIN A · CIK 0001166586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By AH Bio Fund III, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 697,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F3 · ownership.nature: The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.

F4 · ownership.nature: (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001231919-26-000813 · form4-07292026_110744.xml · derivative · entry 4

AH Bio Fund II, L.P. · CIK 0001725721 · 10% owner

AH Equity Partners Bio II, L.L.C. · CIK 0001725722 · 10% owner

AH Bio Fund III, L.P. · CIK 0001799477 · 10% owner

AH Equity Partners Bio III, L.L.C. · CIK 0001799478 · 10% owner

Andreessen Marc L · CIK 0001160077 · 10% owner

HOROWITZ BENJAMIN A · CIK 0001166586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By AH Bio Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,051,742 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F2 · ownership.nature: The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001231919-26-000813 · form4-07292026_110744.xml · nonDerivative · entry 3

AH Bio Fund II, L.P. · CIK 0001725721 · 10% owner

AH Equity Partners Bio II, L.L.C. · CIK 0001725722 · 10% owner

AH Bio Fund III, L.P. · CIK 0001799477 · 10% owner

AH Equity Partners Bio III, L.L.C. · CIK 0001799478 · 10% owner

Andreessen Marc L · CIK 0001160077 · 10% owner

HOROWITZ BENJAMIN A · CIK 0001166586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By AH Bio Fund II, L.P.

Disclosed balance after: 2,385,075

F2 · ownership.nature: The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001231919-26-000813 · form4-07292026_110744.xml · nonDerivative · entry 2

AH Bio Fund II, L.P. · CIK 0001725721 · 10% owner

AH Equity Partners Bio II, L.L.C. · CIK 0001725722 · 10% owner

AH Bio Fund III, L.P. · CIK 0001799477 · 10% owner

AH Equity Partners Bio III, L.L.C. · CIK 0001799478 · 10% owner

Andreessen Marc L · CIK 0001160077 · 10% owner

HOROWITZ BENJAMIN A · CIK 0001166586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By AH Bio Fund III, L.P.

Disclosed balance after: 697,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F3 · ownership.nature: The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.

F4 · ownership.nature: (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001231919-26-000813 · form4-07292026_110744.xml · nonDerivative · entry 1

AH Bio Fund II, L.P. · CIK 0001725721 · 10% owner

AH Equity Partners Bio II, L.L.C. · CIK 0001725722 · 10% owner

AH Bio Fund III, L.P. · CIK 0001799477 · 10% owner

AH Equity Partners Bio III, L.L.C. · CIK 0001799478 · 10% owner

Andreessen Marc L · CIK 0001160077 · 10% owner

HOROWITZ BENJAMIN A · CIK 0001166586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By AH Bio Fund II, L.P.

Disclosed balance after: 2,051,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.

F2 · ownership.nature: The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0000947871-26-000734 · ownership.xml · derivative · entry 3

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 348,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000734 · ownership.xml · nonDerivative · entry 2

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,348,825

F2 · shares: Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000734 · ownership.xml · nonDerivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 348,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.

F3 · ownership.nature: The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001739090-26-000010 · form4-07292026_080745.xml · derivative · entry 2

Doudna Jennifer A · CIK 0001739090 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,511 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.

F1 · price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.

SEC source: 0001739090-26-000010 · form4-07292026_080745.xml · nonDerivative · entry 1

Doudna Jennifer A · CIK 0001739090 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 603,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.

SEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 2

Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks

Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks

Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,080,983

F2 · price: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

SEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 1

Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks

Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks

Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,030,983

F1 · price: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").

F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

SEC source: 0000902664-26-003254 · ownership.xml · derivative · entry 1

Aghazadeh Behzad · CIK 0001701815 · Director · See Remarks

Avoro Capital Advisors LLC · CIK 0001633313 · Director · See Remarks

Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,725

Underlying: Common Stock · 14,725 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date.

F2 · ownership.direct: This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

F3 · ownership.direct: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 4

Lucas Svetlana · CIK 0001781292 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,426

Underlying: Common Stock · 109,426 shares

Expires 2036-07-22

F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 3

Lucas Svetlana · CIK 0001781292 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,426

Underlying: Common Stock · 109,426 shares

Expires 2036-07-22

F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001781292-26-000007 · form4-07282026_010709.xml · nonDerivative · entry 1

Lucas Svetlana · CIK 0001781292 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 3,000

SEC source: 0002127814-26-000004 · form4-07282026_010711.xml · derivative · entry 3

Oakes Benjamin L. · CIK 0002127814 · Director · President, CEO · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 429,599

Underlying: Common Stock · 429,599 shares

Expires 2036-07-22

F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002127814-26-000004 · form4-07282026_010711.xml · derivative · entry 2

Oakes Benjamin L. · CIK 0002127814 · Director · President, CEO · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,784

Underlying: Common Stock · 264,784 shares

Expires 2036-07-22

F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002130384-26-000004 · form4-07282026_010712.xml · derivative · entry 1

Watson James Dean · CIK 0002130384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,725

Underlying: Common Stock · 14,725 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001282930-26-000004 · form4-07282026_010758.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,725

Underlying: Common Stock · 14,725 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002075052-26-000004 · form4-07282026_010701.xml · derivative · entry 1

Bleharski Joshua · CIK 0002075052 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,725

Underlying: Common Stock · 14,725 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 5

Parrot David · CIK 0002127908 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,426

Underlying: Common Stock · 109,426 shares

Expires 2036-07-22

F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 4

Parrot David · CIK 0002127908 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,426

Underlying: Common Stock · 109,426 shares

Expires 2036-07-22

F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002127908-26-000004 · form4-07282026_010722.xml · nonDerivative · entry 2

Parrot David · CIK 0002127908 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child

Disclosed balance after: 1,333

SEC source: 0002127908-26-000004 · form4-07282026_010722.xml · nonDerivative · entry 1

Parrot David · CIK 0002127908 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,333

SEC source: 0002147277-26-000003 · form4-07282026_080735.xml · derivative · entry 3

Staahl Brett · CIK 0002147277 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,385

Underlying: Common Stock · 19,385 shares

Expires 2036-07-22

F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0002147277-26-000003 · form4-07282026_080735.xml · derivative · entry 2

Staahl Brett · CIK 0002147277 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,385

Underlying: Common Stock · 19,385 shares

Expires 2036-07-22

F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 2

Lucas Svetlana · CIK 0001781292 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,547

Underlying: Common Stock · 9,547 shares

Expires 2036-03-12

F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0002127814-26-000004 · form4-07282026_010711.xml · derivative · entry 1

Oakes Benjamin L. · CIK 0002127814 · Director · President, CEO · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,969

Underlying: Common Stock · 12,969 shares

Expires 2036-03-12

F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0002127908-26-000004 · form4-07282026_010722.xml · derivative · entry 3

Parrot David · CIK 0002127908 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,909

Underlying: Common Stock · 8,909 shares

Expires 2036-03-12

F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0002147277-26-000003 · form4-07282026_080735.xml · derivative · entry 1

Staahl Brett · CIK 0002147277 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,755

Underlying: Common Stock · 4,755 shares

Expires 2036-03-12

F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

F2 · derivative.exercise_date: The option is fully vested.